Email Updates

Search form

You are here

AVAC in the News

  • Precisely because of the overwhelming success in recent years of oral PrEP -- which various large studies have found to prevent HIV by anywhere between 90 to 100 percent -- that the future of the douche and other sorts of topically applied anti-HIV agents, such as gels and dissolvable films, all loosely termed "microbicides," is suddenly up in the air, if not outright doomed.

    March 1, 2018
    The Body
  • Advocates working to end the AIDS epidemic fear they may lose ground under the Trump administration after coming within reach of ending the disease’s siege in the US and abroad.

    February 27, 2018
    The Hill
  • Several vaccines and drugs for preventing the spread of HIV are showing signs of success in clinical trials, three decades after scientists began the search. But some researchers fear that progress will stall without a coordinated strategy to ensure that the most promising therapies to prevent infection win support from policymakers and reach the people who need them.

    February 27, 2018
    Nature
  • The Initiative for Multi-Purpose Technologies (IMPT) has published these remarks on the role of end-user research in the development of multi-purpose technologies (MPTs). Leading experts, including AVAC's Anabel Gomez, reflect on considerations for applying this research effectively while framing a few central questions it can address.

    December 21, 2017
    IMPT
  • Six short videos describe how a Kenyan nonprofit organization tackles one of Africa’s toughest missions: helping young women protect themselves against HIV.

    December 15, 2017
    The New York Times
  • A Kaiser Family Foundation web briefing navigated the HIV/AIDS funding landscape, taking a look at trends over time, the latest data, and what we might expect in the future. When analyzing federal funding by the US government for HIV both home and abroad since the first AIDS cases were identified in 1981, “you notice a very dramatic, steep rise at different points, and generally a rise over time,” said Jen Kates, vice president, director of global health and HIV policy, Kaiser Family Foundation.

    December 11, 2017
    General
    AJMC
  • AVAC Policy Director Kevin Fisher appeared on CGTN to discuss the role of governments and private industry in addressing prevention, the search for a cure, and overall costs.

    December 6, 2017
    CGTN America
  • About a dozen new types of microbicides are in the research pipeline, including some that could protect women against not only HIV infection but also other sexually transmitted infections and unwanted pregnancies. But this progress is in peril.

    November 23, 2017
    Bhekisisa
  • Describing the value of working with funders, sponsors, industry partners, governments and community members during all stages of tuberculosis vaccine research and development, the Good Participatory Practice Guidelines for TB Vaccine Research released the first day of this conference is the latest step in a movement to ensure those most affected by science inform its discoveries.

    October 17, 2017
    General
    Science Speaks
  • With the annual IDWeek conference fast approaching, thousands of leading physicians and researchers will once again gather to learn about cutting-edge research on HIV prevention, treatment and cures—and to discuss how to apply that research in ways that can directly benefit people living with HIV today.

    September 29, 2017
    BodyPro

Pages